The all-in-one platform to find and track your stocks and investments
Discover the features
Statistics
Market Cap
871 million
PE Ratio
-
Beta (volatility)
1.19
Earnings Per Share
-1.51
About
ISIN : US92025Y1038
Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell...
Price
Performance Comparison
| Valneva SE ADR | |
|---|---|
| 1 year return |
+59 %
|
| 5 years return | - |
Valuation
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 4.97 | 0 % |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| 5.14 | -7.74 | 4.56 |
Price–Earnings Ratio History
The Price–Earnings Ratio history is not available for this stock.
Dividend History
It looks like no dividends is being distributed for this stock...
Number of Outstanding Shares
Financials
Year-over-Year growth
Profitability
Health
News
VALNEVA Declaration of shares and voting rights: October 31, 2025
11/5/2025
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
11/4/2025
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
10/27/2025
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
10/6/2025
VALNEVA Declaration of shares and voting rights: September 30, 2025
10/6/2025
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
9/30/2025
A Lyme Disease Vaccine’s Final Test Results Could Appear By Yearend.
9/9/2025
VALNEVA Declaration of shares and voting rights: August 31, 2025
9/3/2025
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
9/3/2025
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
8/25/2025
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
8/12/2025
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
8/7/2025
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2026 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.